Marketing Status and Brand‐Name Drug Prices: Evidence From Rx‐To‐OTC Switch

Lin Lin and Bo Wang

Health Economics, 2025, vol. 34, issue 6, 1064-1084

Abstract: This study examines the impact of marketing status on brand‐name pricing by exploiting Prescription to over‐the‐counter (Rx‐to‐OTC) switches between 2001 and 2016. Using a Stacked difference‐in‐differences design, we find that the retail prices of brand‐name drugs reduce substantially following an Rx‐to‐OTC switch, while accounting for potential confounding factors related to patent expiration and generic entry. We show that the reduction in branded prices is primarily driven by increases in patient price elasticity in the OTC market. These results highlight the need to improve patient price sensitivity to address the rising prices of brand‐name prescription drugs in the United States, especially those with characteristics similar to over‐the‐counter drugs.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1002/hec.4952

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:34:y:2025:i:6:p:1064-1084

Access Statistics for this article

Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().